Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
Celgene Provides REVLIMID ® Regulatory Update REVLIMID Granted Approval for Treatment of Patients with Relapsed or Refractory Multiple Myeloma in China REVLIMID ...
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Focalin XR was later launched by Celgene and Novartis in 2005.
The loss of exclusivity for its key drugs in the near future is a cause for concern
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
When it comes to drug pricing, European regulators are a tough sell. Just ask Johnson & Johnson . The U.K.'s National Institute for Health and Care Excellence, or NICE, took a pass on paying for ...
REVLIMID net sales anticipated to be in the range of $4.1 billion to $4.2 billion, an increase of 9 to 12 percent year-over-year, 11 to 14 percent on a constant currency basis